NASA is considering using the popular benchmarking tool CapFrameX to measure the frame rate of its new cockpit simulator systems. These hand-built systems are designed to emulate the latest supersonic ...

Add Yahoo as a preferred source to see more of our stories on Google. A masked U.S. Immigration and Customs Enforcement agent knocks on a car window in Minnesota on Jan. 12. A new court ruling allows ...

The rapid expansion of data centers in the US is placing significant strain on the electric grid, prompting grid operators in multiple states to propose temporary power outages for data centers during ...

Organizations have a wealth of unstructured data that most AI models can’t yet read. Preparing and contextualizing this data is essential for moving from AI experiments to measurable results. In ...

Facing multi-year waits for electrical grid connections, data center operators supporting artificial intelligence (AI) workloads are turning to an unexpected supplier: supersonic jet engine ...

Interior design guru MaCenna Lee makes a DIY frame to turn a TV into art for stylish living spaces. More allegations surface in Minnesota fraud probe Taylor Swift cried offstage at her first concert ...

The new managed functions will let enterprises apply LLM reasoning to structured and unstructured data directly in SQL, eliminating prompt tuning and external tools. Google has boosted its BigQuery ...

We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...

BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to 27 months, keeping alive one of the last remaining hopes for this ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this ...